Neuromodulation Devices Market Scope And Analysis

Report Code : TIPRE00018069
Category : Medical Device

No. of Pages : 150

Buy Now

Neuromodulation Devices Market Scope and Key Players Analysis by 2030

Buy Now

Neuromodulation Devices Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 5.73 Billion
Market Size by 2030	US$ 11.61 Billion
Global CAGR (2022 - 2030)	9.2%
Historical Data	2020-2022
Forecast period	2022-2030
Segments Covered	By Type Internal External By Application Deep Brain Stimulation Sacral Nerve Stimulation Gastric Electrical Stimulation Spinal Cord Stimulation Vagus Nerve Stimulation By Biomaterial Metallic Polymeric Ceramic By End User Hospitals Clinics Home Healthcare
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Abbott St Jude Medical Inc LivaNova PLC Boston Scientific Corporation Aleva Neurotherapeutics SA Bioventus EnteroMedics Inc Nevro Corporation NeuroPace Inc Synapse Biomedical Inc

Competitive Landscape and Key Companies:

The neuromodulation devices market report is focused on prominent players in the market such as Abbott (St. Jude Medical, Inc), LivaNova PLC, Boston Scientific Corporation, Aleva Neurotherapeutics SA, Bioventus, EnteroMedics Inc, Nevro Corporation, NeuroPace Inc, Synapse Biomedical Inc, and Neurosigma Inc. The neuromodulation devices market forecast can help stakeholders plan their growth strategies. These companies focus on new technologies, upgrading existing products, and market expansions to meet the growing consumer demand across the world. As per company press releases, below are a few recent key developments:

In August 2023, Medtronic plc received CE Mark approval for its Inceptiv closed-loop rechargeable spinal cord stimulator (SCS). It is the first Medtronic SCS device to offer a closed-loop feature that senses each person's unique biological signals and adjusts stimulation moment to moment, as needed, to keep therapy in harmony with the motions of daily life.
In August 2023, Abbott received approval from the US Food and Drug Administration (FDA) for its new Proclaim Plus spinal cord stimulation (SCS) system featuring FlexBurst360 therapy. The next generation of Abbott's proprietary BurstDR stimulation, FlexBurst360 therapy offers pain coverage across six areas of the trunk and/or limbs. It facilitates programming that can be adjusted as per a person’s therapeutic needs.